Do analysts recommend PPCB or ERNA?

Ernexa Therapeutics has a consensus price target of $30.00, indicating a potential upside of 1,321.80%. Given Ernexa Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Ernexa Therapeutics is more favorable than Propanc Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ernexa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PPCB or ERNA more profitable?

Propanc Biopharma's return on equity of -171.31% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Propanc Biopharma N/A -171.31% -125.33% Ernexa Therapeutics N/A -305.93% -169.86%

Does the media refer more to PPCB or ERNA?

In the previous week, Propanc Biopharma had 1 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 5 mentions for Propanc Biopharma and 4 mentions for Ernexa Therapeutics. Ernexa Therapeutics' average media sentiment score of 0.07 beat Propanc Biopharma's score of -0.07 indicating that Ernexa Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Propanc Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ernexa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer PMCB or PPCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, PMCB or PPCB?

Nuvilex is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvilex N/A N/A -$19.42M -$2.31 N/A Propanc Biopharma N/A N/A -$18.86M -$24.25 N/A

Is PMCB or PPCB more profitable?

Nuvilex's return on equity of -12.99% beat Propanc Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Nuvilex N/A -12.99% -8.92% Propanc Biopharma N/A -171.31% -125.33%

Do analysts prefer HCWB or PPCB?

HCW Biologics presently has a consensus price target of $30.00, indicating a potential upside of 2,464.10%. Given HCW Biologics' stronger consensus rating and higher possible upside, equities research analysts plainly believe HCW Biologics is more favorable than Propanc Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HCW Biologics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer HCWB or PPCB?

In the previous week, HCW Biologics and HCW Biologics both had 5 articles in the media. HCW Biologics' average media sentiment score of 0.49 beat Propanc Biopharma's score of -0.07 indicating that HCW Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HCW Biologics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Propanc Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer EVGN or PPCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is EVGN or PPCB more profitable?

Propanc Biopharma has a net margin of 0.00% compared to Evogene's net margin of -694.18%. Evogene's return on equity of -156.53% beat Propanc Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Evogene -694.18% -156.53% -86.80% Propanc Biopharma N/A -171.31% -125.33%

Does the media favor EVGN or PPCB?

In the previous week, Propanc Biopharma had 1 more articles in the media than Evogene. MarketBeat recorded 5 mentions for Propanc Biopharma and 4 mentions for Evogene. Evogene's average media sentiment score of 0.37 beat Propanc Biopharma's score of -0.07 indicating that Evogene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evogene 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Propanc Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PPCB or MBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, PPCB or MBIO?

Mustang Bio is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Propanc Biopharma N/A N/A -$18.86M -$24.25 N/A Mustang Bio N/A N/A -$1.92M -$0.45 N/A

Is PPCB or MBIO more profitable?

Mustang Bio's return on equity of -34.23% beat Propanc Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Propanc Biopharma N/A -171.31% -125.33% Mustang Bio N/A -34.23% -17.55%

Propanc Biopharma (PPCB) Competitors

$0.37 -0.05 (-11.35%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$0.38 +0.01 (+3.64%)

As of 05:54 AM Eastern

Compare

PPCB vs. ERNA, PMCB, HCWB, EVGN, and MBIO

Should you buy Propanc Biopharma stock or one of its competitors? Propanc Biopharma's main competitors and comparable companies include Ernexa Therapeutics (ERNA), Nuvilex (PMCB), HCW Biologics (HCWB), Evogene (EVGN), and Mustang Bio (MBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Propanc Biopharma compare to Ernexa Therapeutics?

Propanc Biopharma (NASDAQ:PPCB) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Propanc Biopharma had 1 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 5 mentions for Propanc Biopharma and 4 mentions for Ernexa Therapeutics. Ernexa Therapeutics' average media sentiment score of 0.07 beat Propanc Biopharma's score of -0.07 indicating that Ernexa Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Propanc Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ernexa Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Propanc Biopharma has a beta of 3.53, meaning that its share price is 253% more volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.63, meaning that its share price is 163% more volatile than the broader market.

Ernexa Therapeutics has higher revenue and earnings than Propanc Biopharma. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$18.86M	-$24.25	N/A
Ernexa Therapeutics	$580K	5.93	-$14.08M	-$14.35	N/A

70.6% of Ernexa Therapeutics shares are owned by institutional investors. 28.7% of Propanc Biopharma shares are owned by company insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Propanc Biopharma's return on equity of -171.31% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-171.31%	-125.33%
Ernexa Therapeutics	N/A	-305.93%	-169.86%

Ernexa Therapeutics has a consensus price target of $30.00, indicating a potential upside of 1,321.80%. Given Ernexa Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Ernexa Therapeutics is more favorable than Propanc Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Ernexa Therapeutics beats Propanc Biopharma on 8 of the 13 factors compared between the two stocks.

How does Propanc Biopharma compare to Nuvilex?

Nuvilex (NASDAQ:PMCB) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Nuvilex has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.53, indicating that its stock price is 253% more volatile than the broader market.

In the previous week, Propanc Biopharma had 3 more articles in the media than Nuvilex. MarketBeat recorded 5 mentions for Propanc Biopharma and 2 mentions for Nuvilex. Nuvilex's average media sentiment score of 0.39 beat Propanc Biopharma's score of -0.07 indicating that Nuvilex is being referred to more favorably in the media.

Company	Overall Sentiment
Nuvilex	Neutral
Propanc Biopharma	Neutral

Nuvilex is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	-$19.42M	-$2.31	N/A
Propanc Biopharma	N/A	N/A	-$18.86M	-$24.25	N/A

Nuvilex's return on equity of -12.99% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	-12.99%	-8.92%
Propanc Biopharma	N/A	-171.31%	-125.33%

34.2% of Nuvilex shares are owned by institutional investors. 11.0% of Nuvilex shares are owned by insiders. Comparatively, 28.7% of Propanc Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Nuvilex beats Propanc Biopharma on 5 of the 9 factors compared between the two stocks.

How does Propanc Biopharma compare to HCW Biologics?

HCW Biologics (NASDAQ:HCWB) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

HCW Biologics presently has a consensus price target of $30.00, indicating a potential upside of 2,464.10%. Given HCW Biologics' stronger consensus rating and higher possible upside, equities research analysts plainly believe HCW Biologics is more favorable than Propanc Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Propanc Biopharma has a net margin of 0.00% compared to HCW Biologics' net margin of -83.03%. Propanc Biopharma's return on equity of -171.31% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-83.03%	-262.33%	-34.90%
Propanc Biopharma	N/A	-171.31%	-125.33%

HCW Biologics has higher revenue and earnings than Propanc Biopharma. HCW Biologics is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$50K	52.42	-$7.96M	-$27.60	N/A
Propanc Biopharma	N/A	N/A	-$18.86M	-$24.25	N/A

In the previous week, HCW Biologics and HCW Biologics both had 5 articles in the media. HCW Biologics' average media sentiment score of 0.49 beat Propanc Biopharma's score of -0.07 indicating that HCW Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HCW Biologics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Propanc Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

HCW Biologics has a beta of 2.41, indicating that its share price is 141% more volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.53, indicating that its share price is 253% more volatile than the broader market.

3.0% of HCW Biologics shares are owned by institutional investors. 9.1% of HCW Biologics shares are owned by insiders. Comparatively, 28.7% of Propanc Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

HCW Biologics beats Propanc Biopharma on 8 of the 14 factors compared between the two stocks.

How does Propanc Biopharma compare to Evogene?

Evogene (NASDAQ:EVGN) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

Evogene has higher revenue and earnings than Propanc Biopharma. Evogene is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evogene	$3.85M	0.86	-$8.48M	-$0.91	N/A
Propanc Biopharma	N/A	N/A	-$18.86M	-$24.25	N/A

Propanc Biopharma has a net margin of 0.00% compared to Evogene's net margin of -694.18%. Evogene's return on equity of -156.53% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evogene	-694.18%	-156.53%	-86.80%
Propanc Biopharma	N/A	-171.31%	-125.33%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Evogene has a beta of 1.44, indicating that its stock price is 44% more volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.53, indicating that its stock price is 253% more volatile than the broader market.

In the previous week, Propanc Biopharma had 1 more articles in the media than Evogene. MarketBeat recorded 5 mentions for Propanc Biopharma and 4 mentions for Evogene. Evogene's average media sentiment score of 0.37 beat Propanc Biopharma's score of -0.07 indicating that Evogene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evogene	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Propanc Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

10.4% of Evogene shares are held by institutional investors. 7.4% of Evogene shares are held by company insiders. Comparatively, 28.7% of Propanc Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Evogene beats Propanc Biopharma on 7 of the 11 factors compared between the two stocks.

How does Propanc Biopharma compare to Mustang Bio?

Propanc Biopharma (NASDAQ:PPCB) and Mustang Bio (NASDAQ:MBIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

9.9% of Mustang Bio shares are held by institutional investors. 28.7% of Propanc Biopharma shares are held by insiders. Comparatively, 4.0% of Mustang Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Propanc Biopharma has a beta of 3.53, indicating that its share price is 253% more volatile than the broader market. Comparatively, Mustang Bio has a beta of 2.09, indicating that its share price is 109% more volatile than the broader market.

Mustang Bio's return on equity of -34.23% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-171.31%	-125.33%
Mustang Bio	N/A	-34.23%	-17.55%

Mustang Bio is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$18.86M	-$24.25	N/A
Mustang Bio	N/A	N/A	-$1.92M	-$0.45	N/A

In the previous week, Propanc Biopharma had 4 more articles in the media than Mustang Bio. MarketBeat recorded 5 mentions for Propanc Biopharma and 1 mentions for Mustang Bio. Mustang Bio's average media sentiment score of 1.82 beat Propanc Biopharma's score of -0.07 indicating that Mustang Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Propanc Biopharma	Neutral
Mustang Bio	Very Positive

Summary

Mustang Bio beats Propanc Biopharma on 6 of the 10 factors compared between the two stocks.

Get Propanc Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PPCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PPCB vs. The Competition

Export

Metric	Propanc Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.61M	$3.84B	$7.18B	$13.18B
Dividend Yield	N/A	3.65%	2.52%	19.59%
P/E Ratio	-0.02	10.48	216.61	19.63
Price / Sales	N/A	1,147.33	565.61	77.64
Price / Cash	N/A	119.79	76.68	52.75
Price / Book	0.13	16.17	10.37	5.92
Net Income	-$18.86M	-$22.69M	$3.50B	$380.90M
7 Day Performance	-22.36%	-5.84%	-3.51%	-3.90%
1 Month Performance	-55.40%	-12.90%	-7.78%	-6.42%
1 Year Performance	-99.15%	3.16%	0.86%	-6.01%

Propanc Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PPCB Propanc Biopharma	0.4222 of 5 stars	$0.37 -11.3%	N/A	-99.2%	$2.61M	N/A	N/A	2	Short Interest Increase Gap Up High Trading Volume
ERNA Ernexa Therapeutics	2.5375 of 5 stars	$2.70 -8.8%	$30.00 +1,011.1%	-93.5%	$4.40M	$580K	N/A	5
PMCB Nuvilex	0.5952 of 5 stars	$0.39 -2.5%	N/A	-66.2%	$4.19M	N/A	N/A	2	News Coverage Short Interest Increase
HCWB HCW Biologics	3.2378 of 5 stars	$1.64 -2.4%	$30.00 +1,729.3%	-95.7%	$3.67M	$50K	N/A	35
EVGN Evogene	1.0514 of 5 stars	$0.40 -5.0%	N/A	-70.8%	$3.52M	$3.85M	N/A	52	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PPCB) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Propanc Biopharma (PPCB) Competitors

PPCB vs. ERNA, PMCB, HCWB, EVGN, and MBIO

How does Propanc Biopharma compare to Ernexa Therapeutics?

Summary

How does Propanc Biopharma compare to Nuvilex?

Summary

How does Propanc Biopharma compare to HCW Biologics?

Summary

How does Propanc Biopharma compare to Evogene?

Summary

How does Propanc Biopharma compare to Mustang Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPCB vs. The Competition

Propanc Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Propanc Biopharma (PPCB) Competitors

PPCB vs. ERNA, PMCB, HCWB, EVGN, and MBIO

How does Propanc Biopharma compare to Ernexa Therapeutics?

Does the media refer more to PPCB or ERNA?

Which has more risk and volatility, PPCB or ERNA?

Which has preferable earnings and valuation, PPCB or ERNA?

Do insiders & institutionals have more ownership in PPCB or ERNA?

Is PPCB or ERNA more profitable?

Do analysts recommend PPCB or ERNA?

Summary

How does Propanc Biopharma compare to Nuvilex?

Which has more risk & volatility, PMCB or PPCB?

Does the media prefer PMCB or PPCB?

Which has higher earnings & valuation, PMCB or PPCB?

Is PMCB or PPCB more profitable?

Do institutionals & insiders have more ownership in PMCB or PPCB?

Do analysts prefer PMCB or PPCB?

Summary

How does Propanc Biopharma compare to HCW Biologics?

Do analysts prefer HCWB or PPCB?

Is HCWB or PPCB more profitable?

Which has stronger valuation and earnings, HCWB or PPCB?

Does the media prefer HCWB or PPCB?

Which has more volatility and risk, HCWB or PPCB?

Do insiders and institutionals have more ownership in HCWB or PPCB?

Summary

How does Propanc Biopharma compare to Evogene?

Which has preferable earnings & valuation, EVGN or PPCB?

Is EVGN or PPCB more profitable?

Do analysts prefer EVGN or PPCB?

Which has more volatility and risk, EVGN or PPCB?

Does the media favor EVGN or PPCB?

Do insiders and institutionals believe in EVGN or PPCB?

Summary

How does Propanc Biopharma compare to Mustang Bio?

Do insiders & institutionals believe in PPCB or MBIO?

Do analysts rate PPCB or MBIO?

Which has more risk & volatility, PPCB or MBIO?

Is PPCB or MBIO more profitable?

Which has stronger valuation & earnings, PPCB or MBIO?

Does the media favor PPCB or MBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPCB vs. The Competition

Propanc Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools